

Pharmerit Staff Publications by Therapeutic Area



1 Cardiovascular

Willich SN, Chuang LH, **van Hout B**, Gumbs P, Jimenez D, **Kroep S**, Bauersachs R, Monreal M, Agnelli G, Cohen A. Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. *Thromb Res*. 2018 Feb 16;170:181-191. doi: 10.1016/j.thromres.2018.02.009. [Epub ahead of print]

Bangalore S, **Shah R**, Pappadopulos E, **Deshpande CG**, **Shelbaya A**, Prieto R, **Stephens J**, McIntyre RS. Cardiovascular Hazards of Insufficient Treatment of Depression Among Patients with Known Cardiovascular Disease: A Propensity Score Adjusted Analysis: Bangalore et al, CVD Hazards of Insufficient Depression Treatment. *Eur Heart J Qual Care Clin Outcomes*. 2018 Jun 11. doi: 10.1093/ehjqcco/qcy023. [Epub ahead of print]

Schmidt R, **Majer I**, García Román N, Rivas Basterra A, Grubb E, Medrano López C. Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain. *Health Econ Rev*. 2017 Dec 19;7(1):47. doi: 10.1186/s13561-017-0181-3.

Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, **van Hout B**, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. *JAMA Cardiol*. 2017 Oct 1;2(10):1069-1078. doi: 10.1001/jamacardio.2017.2762.

Heisen M, **Treur MJ**, Heemstra HE, Giesen EBW, Postma MJ. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. *J Med Econ*. 2017 Jun 25:1-12. doi: 10.1080/13696998.2017.1331912.

Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, **van Hout B**. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. *Clin Cardiol*. 2016 Jun;39(6):313-20. doi: 10.1002/clc.22535.

Vandigo J, Oloyede E, **Aly A**, Laird AL, Cooke CE, Mullins CD. Continuous patient engagement in cardiovascular disease comparative clinical effectiveness research. *Expert Rev Pharmacoecon Outcomes Res*. 2016;16(2):193-198. doi:10.1586/14737167.2016.1163222.

Schmid T, **Xu W**, Gandra SR, Michailov GV. Erratum to: "Costs of treating cardiovascular events in Germany: a systematic literature review." *Health Econ Rev*. 2016;6:1. doi:10.1186/s13561-016-0080-z.



Eckmann C, Nathwani D, Lawson W, **Corman S, Solem C, Stephens J**, Macahilig C, Li J, Charbonneau C, Baillon-Plot N, Haider S. Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated skin and soft-tissue infections due to methicillin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect*. 2015;21(suppl 2):S33-S39. doi:10.1016/j.cmi.2015.01.011.

Begum N, Stephens S, Schoeman O, Fraschke A, Kirsch B, Briere JB, Verheugt FW, **van Hout BA**. Cost-effectiveness analysis of rivaroxaban in the secondary prevention of acute coronary syndromes in Sweden. *Cardiol Ther*. 2015;4(2):131-153. doi:10.1007/s40119-015-0041-3.

Patel V, **Lin FJ**, Ojo O, Rao S, Yu S, Zhan L, Touchette DR. Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. *Pharm Pract (Granada)*. 2014;12(3):438.

Stevanović J, O'Prinsen AC, **Verheggen BG**, Schuiling-Veninga N, Postma MJ, Pechlivanoglou P. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands. *Clin Ther*. 2014;36(3):368-384. doi:10.1016/j.clinthera.2014.01.008.

Villa G, Lothgren M, Gandra SR, Lindgren P, **van Hout B**. Deterministic Versus Stochastic Prediction of Risk for Cardiovascular Events. *Value Health*. 2014 Nov;17(7):A558. doi: 10.1016/j.jval.2014.08.1840. Epub 2014 Oct 26.

Murphy A, **Fenwick E**, Neilson MP, Toff WD, Berry C, Uren NG, Oldroyd KG, Briggs AH. Transcatheter-Aortic-Valve-Replacement for severe aortic stenosis: Cost-effectiveness for inoperable UK patients. *International Journal of Technology Assessment in Health Care*. 2013, 29 (1): 1-8.

McKenna C, Walker S, Lorgelly P, **Fenwick E**, Burch J, Suekarran S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N and Palmer S. Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure. *Value in Health*. 2012, 15 (3): 420-428.

Cohen DJ, Lavelle TA, **van Hout B**, Li H, Lei Y, Robertus K, Pinto D, Magnuson EA, McGarry TF, Lucas SK, Horwitz PA, Henry CA, Serruys PW, Mohr FW, Kappetein AP. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial. *Catheter Cardiovasc Interv*. 2012;79(2):198-209. doi:10.1002/ccd.23147.



Furze G, Cox H, Morton V, **Chuang LH**, Lewin RJ, Nelson P, Carty R, Norris H, Patel N, Elton P. Randomized controlled trial of a lay-facilitated angina management programme. *J Adv Nurs*. 2012;68(10):2267-2279. doi:10.1111/j.1365-2648.2011.05920.x.

Xu W, Hensen M, Steinle T, Pelosi C. PCV35 Costs of treating cardiovascular diseases in Germany: a systematic literature review. *Value Health*. 2012;15(7):A368. doi:10.1016/j.jval.2012.08.978.

Heemstra HE, Nieuwlaat R, **Meijboom M**, Crijns HJ. The burden of atrial fibrillation in the Netherlands. *Netherlands Heart Journal*. 2011;19(9):373-378. doi:10.1007/s12471-011-0175-4.

Watson JM, Kang'ombe AR, Soares MO, **Chuang LH**, Worthy G, Bland JM, Iglesias C, Cullum N, Torgerson D, Nelson EA; VenUS III Team. Use of weekly, low dose, high frequency ultrasound for hard to heal venous leg ulcers: the VenUS III randomised controlled trial. *BMJ*. 2011;342:d1092. doi:10.1136/bmj.d1092.

Cohen DJ, **van Hout B**, Serruys PW, Mohr FW, Macaya C, den Heijer P, Vrakking MM, Wang K, Mahoney EM, Audi S, Leadley K, Dawkins KD, Kappetein AP; SYNTAX Investigators. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. *N Engl J Med*. 2011;364(11):1016-1026. doi:10.1056/NEJMoa1001508.

Thurston SJ, Heeg B, de Charro F, van Hout B. Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial. *Curr Med Res Opin*. 2010;26(3):641-651. doi:10.1185/03007990903529267.

Logman JF, Heeg BM, Herlitz J, **van Hout BA**. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations. *Appl Health Econ Health Policy*. 2010;8(4):251-265. doi:10.2165/11535520-000000000-00000.

Lawson KD, **Fenwick E**, Pell ACH, Pell JP. Comparison of mass and targeted screening strategies for cardiovascular risk: Simulation of the effectiveness, cost-effectiveness and coverage from a cross sectional survey of 3,291 people. *Heart*. 2010, **96 (3)**: 208-212. ISSN 1355-6037

Fenwick E, Marshall D, Blackhouse G, Vidaillet H, Slee A, Shemanski L, Levy AR. Assessing the impact of censoring of costs and effects on health care decision-making: an example using the atrial fibrillation follow-up investigation of rhythm management (affirm) study. *Value in Health*. 2008, 11 (3): 365-375.



Bravo Vergel Y, Palmer S, Asseburg C, **Fenwick E**, de Belder M, Abrams K and Sculpher M. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. *Heart*. 2007, 93 (10): 1238-43.

Asseberg C, Bravo Y, Palmer S, **Fenwick E**, de Belder M, Abrams K, Sculpher M. Assessing the effectiveness of primary angioplasty compared to thrombolysis and its relationship to time delay: a Bayesian evidence synthesis. *Heart*. 2007, 93: 1244-50.

Heeg B, Damen J, **Van Hout B**. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. *Pharmacoeconomics*. 2007;25(12):1063-82.

Heeg BM, Peters RJ, **Botteman M**, **van Hout BA**. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention. *Pharmacoeconomics*. 2007;25(9):769-82.

Heeg B, van Gestel A, **van Hout B**, Olsen J, Haghfelt TH. [Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark]. *Ugeskr Laeger*. 2006 Aug 28;168(35):2911-5.

Buskens E, Meijboom MJ, Kooijman H, **Van Hout BA**. The use of a surgical sealant (CoSeal) in cardiac and vascular reconstructive surgery: an economic analysis. *J Cardiovasc Surg (Torino)*. 2006 Apr;47(2):161-70.

Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. *BMC Health Services Research*. 2006, 6:52.

Marshall D, Levy AR, Vidaillet H, **Fenwick E**, Slee A, Blackhouse G, Greene HL, Wyse DG, Nichol G, O'Brien BJ, and the AFFIRM and CORE Investigators. Cost-Effectiveness of Rhythm Versus Rate Control in Atrial Fibrillation. *Annals of Internal Medicine*. 2004, 141 (9): 653-661.



2 CNS and Mental Health

Tremblay G, Howard D, Tsong W, **Patel V**, De Rosendo J. Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective. *Epilepsy Behav.* 2018 Sep;86:108-115. doi: 10.1016/j.yebeh.2018.06.002. Epub 2018 Jul 9.

Piena MA, Heisen M, Wormhoudt LW, van Wingerden J, Frequin STFM, Uitdehaag BMJ. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. *J Med Econ.* 2018 Jun 18:1-16. doi: 10.1080/13696998.2018.1489255. [Epub ahead of print]

Serrano D, Atzinger CB, **Botteman MF**. Understanding the disease course and therapeutic benefit of tafamidis across real-world studies of hereditary transthyretin amyloidosis with polyneuropathy: A proof of concept for integrative data analytic approaches. *Neurol Ther.* 2018 Jun;7(1):141-154. doi: 10.1007/s40120-018-0096-x. Epub 2018 Apr 2.

Schmidt HH, Waddington-Cruz M, **Botteman MF**, Carter JA, **Chopra AS**, Hopps M, Stewart M, Fallet S, Amass L. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. *Muscle Nerve.* 2018 May;57(5):829-837. doi: 10.1002/mus.26034. Epub 2018 Feb 1

Cruz MW, Schmidt H, **Botteman MF**, Carter JA, **Chopra AS**, Stewart M, Hopps M, Fallet S, Amass L. Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases. *Amyloid.* 2017 Mar;24(sup1):109-110. doi: 10.1080/13506129.2017.1292902.

Schmidt H, Cruz MW, **Botteman MF**, Carter JA, **Chopra A**, Stewart M, Hopps M, Fallet S, Amass L. Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review. *Amyloid.* 2017 Mar;24(sup1):111-112. doi: 10.1080/13506129.2017.1292903.

Tremblay G, Barghout V, **Patel V**, Tsong W, Wang Z. Budget impact of perampanel as adjunctive treatment of uncontrolled partial-onset and primary generalized tonic-clonic seizures in the United States. *Epilepsy Behav.* 2017;68:196-202. doi:10.1016/j.yebeh.2016.12.029.

Sajatovic M, Ng-Mak D, **Solem CT**, **Lin FJ**, Rajagopalan K, Loebel A. Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis. *Ther Adv Psychopharmacol.* 2016;6(6):355-368. doi:10.1177/2045125316672135.



Solem CT, Shelbaya A, **Wan Y**, **Deshpande CG**, Alvir J, Pappadopulos E. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data. *Neuropsychiatr Dis Treat*. 2016;12:2755-2764. doi:10.2147/NDT.S115094.

Fishleder S, Gum AM, **King-Kallimanis BL**, Schonfeld L. Trajectories of depressive symptoms in community-dwelling older adults: a six-month longitudinal study with monthly assessment. *J Affect Disord*. July 1, 2016;198:171-177. doi:10.1016/j.jad.2016.02.058.

Tempest M, Sapin C, Beillat M, Robinson P, **Treur M**. Cost-effectiveness analysis of aripiprazole once-monthly for the treatment of schizophrenia in the UK. *J Ment Health Policy Econ*. 2015;18(4):185-200.

Majer IM, Gaughran F, Sapin C, Beillat M, **Treur M**. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. *J Market Access Health Policy*. 2015;3(1):27208. doi:10.3402/jmahp.v3.27208.

Cooper S, Morrison J, Allan L, McConnachie A, Greenlaw N, Melville C, Baltzer M, McArthur L, Lammie C, Martin G, Grieve E, **Fenwick E**. Practice nurse health checks for adults with intellectual disabilities: a cluster-design, randomised controlled trial. *The Lancet Psychiatry*. 2014, 1 (7): 511-521.

Saylan M, **Treur MJ**, **Postema R**, Dilbaz N, Savas H, **Heeg BM**, Drost PB. Cost-effectiveness analysis of aripiprazole augmentation treatment of major depressive disorder patients compared to olanzapine and quetiapine augmentation in Turkey: a micro-simulation approach. *Value Health Reg Issues*. 2013;2(2):171-180. doi:10.1016/j.vhri.2013.06.004.

Lasch KE, Hassan M, Endicott J, Piau-Luis EC, Locklear J, Fitz-Randolph M, Pathak S, Hwang S, Jernigan K. Development and content validity of a patient reported outcomes measure to assess symptoms of major depressive disorder. *BMC Psychiatry*. 2012;12:34. doi:10.1186/1471-244X-12-34.

Rowen D, Mulhern B, Banerjee S, **van Hout B**, Young TA, Knapp M, Smith SC, Lamping DL, Brazier JE. Estimating preference-based single index measures for dementia using DEMQOL and DEMQOL-Proxy. *Value Health*. 2012;15(2):346-356. doi:10.1016/j.jval.2011.10.016.

Heisen M, **Treur MJ**, van der Hel WS, Frequin ST, Groot MT, **Verheggen BG**. Fingolimod reduces direct medical costs compared to natalizumab in patients with



relapsing-remitting multiple sclerosis in the Netherlands. *J Med Econ.* 2012;15(6):1149-1158. doi:10.3111/13696998.2012.707631.

Treur M, Baca E, Bobes J, Canas F, Salvador L, Gonzalez B, **Heeg B**. The cost-effectiveness of paliperidone extended release in Spain. *J Med Econ.* 2012;15(suppl 1):26-34. doi:10.3111/13696998.2012.734884.

Gu NY, **Botteman MF**, **Ji X**, Bell CF, **Carter JA**, **van Hout B**. Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities. *Health Qual Life Outcomes.* 2011;9:119. doi:10.1186/1477-7525-9-119.

Lasch KE, Abraham L, Patrick J, Piau EC, Tully SE, Treglia M. Development of a next day functioning measure to assess the impact of sleep disturbance due to restless legs syndrome: the restless legs syndrome-next day impact questionnaire. *Sleep Med.* 2011;12(8):754-761. doi:10.1016/j.sleep.2011.03.015.

Raaijmakers MA, Posthumus JA, **van Hout BA**, van Engeland H, Matthys W. Cross-sectional study into the costs and impact on family functioning of 4-year-old children with aggressive behavior. *Prev Sci.* 2011;12(2):192-200. doi:10.1007/s11121-011-0204-y.

Lavsa SM, Fabian TJ, Saul MI, **Corman SL**, Coley KC. Influence of medications and diagnoses on fall risk in psychiatric inpatients. *Am J Health Syst Pharm.* 2010;67(15):1274-1280. doi:10.2146/ajhp090611.

Snedecor SJ, **Botteman MF**, Schaefer K, Sarocco P, Barry N, Pickard AS. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. *J Ment Health Policy Econ.* 2010;13(1):27-35.

Hensen M, **Heeg B**, Lothgren M, **van Hout B**. Cost effectiveness of long-acting risperidone in Sweden. *Appl Health Econ Health Policy.* 2010;8(5):327-341. doi:10.2165/11536180-000000000-00000.

Botteman M. Health economics of insomnia therapy: implications for policy. *Sleep Med.* 2009 Sep;10 Suppl 1:S22-5. doi: 10.1016/j.sleep.2009.07.001. Epub 2009 Jul 31.

Snedecor SJ, **Botteman MF**, Bojke C, Schaefer K, Barry N, Pickard AS. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. *Sleep.* 2009 Jun;32(6):817-24.

Heeg BM, Damen J, Buskens E, Caleo S, de Charro F, **van Hout BA**. Modelling approaches: the case of schizophrenia. *Pharmacoeconomics.* 2008;26(8):633-48.



Treur M, Heeg B, Möller HJ, Schmeding A, **van Hout B**. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. *BMC Health Serv Res*. 2009 Feb 18;9:32. doi: 10.1186/1472-6963-9-32.

Heeg B, Buskens E, **Botteman M**, Caleo S, Ingham M, Damen J, de Charro F, **van Hout B**. The cost-effectiveness of atypicals in the UK. *Value Health*. 2008 Dec;11(7):1007-21. doi: 10.1111/j.1524-4733.2008.00344.x. Epub 2008 May 16.

Damen J, Thuresson PO, **Heeg B**, Lothgren M. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. *Appl Health Econ Health Policy*. 2008;6(4):189-97. doi: 10.2165/00148365-200806040-00002.

Heeg BM, Antunes J, Figueira ML, Jara JM, Marques Teixeira J, Palha AP, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, Van Hout BA. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. *Curr Med Res Opin*. 2008 Feb;24(2):349-58.

Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. *CNS Drugs*. 2007;21(4):319-34.

Heeg B, Buskens E, Knapp M, van Aalst G, Dries PJ, de Haan L, **van Hout BA**. Modelling the treated course of schizophrenia: development of a discrete event simulation model. *Pharmacoeconomics*. 2005;23 Suppl 1:17-33.



3 Digestive System

Delgado-Herrera L, **Lasch K**, Zeiher B, Lembo AJ, Drossman DA, Banderas B, Rosa K, Lademacher C, Arbuckle R. Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population. *Therap Adv Gastroenterol*. 2017 Sep;10(9):673-687. doi: 10.1177/1756283X17726018. Epub 2017 Aug 24.

Lelli F, Nuhoho S, Lee XY, **Xu W**. Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe. *Clin Exp Gastroenterol*. 2016;9:311-323. doi:10.2147/CEG.S109696.

Delgado-Herrera L, **Lasch K**, Popielnicki A, Nishida A, Arbuckle R, Banderas B, Zentner S, Gagainis I, Zeiher B. Cultural adaptation: translatability assessment and linguistic validation of the patient-reported outcome instrument for irritable bowel syndrome with diarrhea. *Patient Relat Outcome Meas*. 2016;7:81-92. doi:10.2147/PROM.S102647.

Solem CT, Patel H, **Mehta S**, Mody R, Macahilig C, **Gao X**. Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype. *Curr Med Res Opin*. 2016;32(5):899-905. doi:10.1185/03007995.2016.1150262.

Lasch K, Delgado-Herrera L, Waldman LT, Rosa K, Spears G, Lembo AJ, Marquis P, Kothari S, Lademacher C, Gagainis I, Zeiher B. Development of a new instrument to assess stool form and consistency in irritable bowel syndrome with diarrhea. *Gastroenterol Hepatol Open Access*. 2016;4(1):00084. doi:10.15406/ghoa.2016.04.00084.

Wan Y, **Corman S**, **Gao X**, **Liu S**, Patel H, Mody R. Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain. *Am Health Drug Benefits*. 2015;8(2):93-102.

Marquis P, **Lasch KE**, Delgado-Herrera L, Kothari S, Lembo A, Lademacher C, Spears G, Nishida A, Tesler WL, Pialt E, Rosa K, Zeiher B. Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome. *Clin Transl Gastroenterol*. 2014;5(6):e59. doi:10.1038/ctg.2014.7.

Solem C, Mody R, **Stephens J**, Macahilig C, **Gao X**. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence. *J Am Pharm Assoc (2003)*. 2014;54(2):144-153. doi:10.1331/JAPhA.2014.13117.



4 Endocrine, Nutritional & Metabolic

Marcus J, **Lasch K**, **Wan Y**, Yang M, Hsu C, Merante D. An Assessment of Clinically Important Differences on the Worst Pain Severity Item of the Modified Brief Pain Inventory in Patients with Diabetic Peripheral Neuropathic Pain. *Pain Res Manag.* 2018 Jul 22;2018:2140420. doi: 10.1155/2018/2140420. eCollection 2018.

Tieu C, Lucas EJ, DePaola M, Rosman L, Alexander GC. Efficacy and safety of biosimilar insulins compared to their reference products : A systematic review. *PLoS One.* 2018 Apr 18;13(4):e0195012. doi: 10.1371/journal.pone.0195012. eCollection 2018.

Lin HM, **Gao X**, **Cooke CE**, Berg D, Labotka R, Faller DV, Seal B, Hari P. Disease burden of systemic light-chain amyloidosis: a systematic literature review. *Curr Med Res Opin.* 2017 Jun;33(6):1017-1031. doi: 10.1080/03007995.2017.1297930.

Chuang LH, **Verheggen BG**, **Charokopou M**, Gibson D, Grandy S, Kartman B. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. *J Med Econ.* 2016;19(12):1127-1134. doi:10.1080/13696998.2016.1203329.

Ostawal A, Mocevic E, Kragh N, **Xu W**. Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. *Diabetes Ther.* 2016;7(3):411-438. doi:10.1007/s13300-016-0180-0.

Wilke T, Mueller S, Groth A, Berg B, Hammar N, Tsai K, Fuchs A, **Stephens S**, Maywald U. Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study. *J Diabetes Metab Disord.* 2016;15:28. doi: 10.1186/s40200-016-0251-9.

Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspective. *BMC Health Serv Res.* 2015;15:496. doi:10.1186/s12913-015-1139-y.

Wilke T, Boettger B, Berg B, Groth A, Mueller S, **Botteman M**, Yu S, Fuchs A, Maywald U. Epidemiology of urinary tract infections in type 2 diabetes mellitus patients: an analysis based on a large sample of 456,586 German T2DM patients. *J Diabetes Complications.* 2015;29(8):1015-1023. doi:10.1016/j.jdiacomp.2015.08.021.

Charokopou M, Sabater FJ, Townsend R, Roudaut M, McEwan P, **Verheggen BG**. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes



mellitus and their use in health technology assessments: a systematic review of the literature from 2008 to 2013. *Curr Med Res Opin.* 2016;32(2):207-218. doi:10.1185/03007995.2015.1102722.

Eckmann C, Nathwani D, Lawson W, **Corman S, Solem C, Stephens J**, Macahilig C, Li J, Charbonneau C, Baillon-Plot N, Haider S. Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated skin and soft-tissue infections due to methicillin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect.* 2015;21(suppl 2):S33-S39. doi:10.1016/j.cmi.2015.01.011.

Heller S, **Houwing N**, Kragh N, Ploug UJ, Nikolajsen A, **Alleman CJ**. Investigating the evidence of the real-life impact of acute hyperglycaemia. *Diabetes Ther.* 2015;6(3):389-393. doi:10.1007/s13300-015-0126-y.

Wyke S, Hunt K, Gray CM, **Fenwick E**, Bunn C, Donnan PT, Rauchhaus P, Mutrie N, Anderson AS, Boyer N, Brady A, Grieve E, White A, Ferrell C, Hindle E, Treweek S. Football Fans in Training (FFIT): a randomized controlled trial of a gender-sensitised weight loss and healthy living programme for men. *Public Health Research.* 2015, 3 (2).

Lopez JM, Macomson B, **Ektare V, Patel D, Botteman M**. Evaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitus. *Am Health Drug Benefits.* 2015;8(6):309-318.

Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitus. *Diabet Med.* 2015;32(7):890-898. doi:10.1111/dme.12772.

Ektare VU, Lopez JM, Martin SC, **Patel DA**, Rupnow MF, **Botteman MF**. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus. *Am J Manag Care.* 2014;20(10):S204-S215.

Turpin RS, **Solem C**, Pontes-Arruda A, Sanon M, **Mehta S**, Xiaoqing Liu F, **Botteman M**. The impact of parenteral nutrition preparation on bloodstream infection risk and costs. *Eur J Clin Nutr.* 2014;68(8):953-958. doi:10.1038/ejcn.2014.34.

Ul-Haq Z, Mackay D, **Fenwick E**, Pell J. Association between body mass index and mental health among Scottish adult population: a cross-sectional study of 37,272 participants. *Psychological Medicine.* 2014, 44 (10): 2231-2240.

Hunt K, Wyke S, Gray CM, Anderson AS, Brady A, Bunn C, Donnan PT, **Fenwick E**, Grieve E, Leishman J, Miller E, Mutrie N, Rauchhaus P, White A, Treweek S. A



gender-sensitised weight loss and healthy living programme for overweight and obese men delivered by Scottish Premier League football clubs (FFIT): A pragmatic randomised controlled trial. *The Lancet*. 2014, 383 (9924): 1211-1221.

Varni JW, Curtis BH, Abetz LN, **Lasch KE**, Piau EC, Zeytoonjian AA. Content validity of the PedsQL™ 3.2 Diabetes Module in newly diagnosed patients with type 1 diabetes mellitus ages 8-45. *Qual Life Res*. 2013;22(8):2169-2181. doi:10.1007/s11136-012-0339-8.

Liu FX, **Botteman M**, **Patel DA**, DeLegge MH, Mercaldi CJ, Turpin RS. Cost effectiveness analysis of parenteral nutrition therapies among hospitalized patients: multi-chamber bag system vs. compounding. *Int J Healthc Technol Manage*. 2013;14(3):176. doi:10.1504/IJHTM.2014.064246.

Grieve E, **Fenwick E**, Yang H-C, Lean M. The disproportionate economic burden associated with severe and complicated obesity: a systematic review. 2013, 14 (11): 883-894.

Lawson K, Mercer S, Wyke S, Grieve E, Guthrie B, Watt G, **Fenwick E**. Double trouble: the impact of multimorbidity and deprivation on preference-weighted health related quality of life a cross sectional analysis of the Scottish Health Survey. *International Journal for Equity in Health*. 2013, 12 (1): 67-76.

Ul-Haq Z, Mackay D, **Fenwick E**, Pell J. Meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the SF-36. *Obesity*. 2013, 21 (3): E322-E327.

Ul-Haq Z, Mackay D, **Fenwick E**, Pell J. Meta-analysis of the association between body mass index and health-related quality of life among children and adolescents, assessed using the PedsQL index. *The Journal of Pediatrics*. 2013, 162 (2): 280-286.

Wyke S, Hunt K, Gray CM, Anderson AS, Brady A, Donnan PT, **Fenwick E**, Leishman J, Mutrie N, Singh B, Treweek S and White A. Football Fans in Training (FFIT): a pragmatic randomized controlled trial of a gender-sensitised weight loss and healthy living programme delivered to men aged 35-65 by Scottish Premier League (SPL) football clubs. *Lancet*. 2012, ISSN 0140-6736

Ul-Haq Z, Mackay D, **Fenwick E**, Pell J. Impact of metabolic comorbidity on the association between body mass index and health related quality of life: a Scotland-wide cross-sectional study of 5,608 participants. *BMC Public Health*. 2012, 12:143.



Ben-Shlomo A, Sheppard MC, **Stephens JM**, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. *Pituitary*. 2011;14(3):284-294. doi:10.1007/s11102-011-0310-7.

Majer IM, Nusselder WJ, Mackenbach JP, Kunst AE. Life expectancy and life expectancy with disability of normal weight, overweight, and obese smokers and nonsmokers in Europe. *Obesity (Silver Spring)*. 2011;19(7):1451-1459. doi:10.1038/oby.2011.46.

Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. *J Manag Care Pharm*. 2006 Mar;12(2):130-42.

Fenwick E, Briggs A, Hawke C. Management of urinary tract infection in general practice: a cost-effectiveness analysis. *British Journal of General Practice*. 2000, 50: 635-639.



5 Genitourinary System

Snedecor SJ. Review of Economic Value Drivers of the Treatment of Overactive Bladder. *Pharmacoeconomics*. 2018 May 4. doi: 10.1007/s40273-018-0663-0.

Angulo JC, Sánchez-Ballester F, Peral C, Rejas J, Ramos J, **Snedecor SJ**, **Sudharshan L**, **Liu S**, Luo X. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective. *Actas Urol Esp*. 2016;40(8):513-522. doi:10.1016/j.acuro.2015.11.012.

Qin L, Luo X, Zou KH, **Snedecor SJ**. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States. *J Med Econ*. 2016;19(3):229-235. doi:10.3111/13696998.2015.1111893.

Heisen M, **Baeten SA**, **Verheggen BG**, Stoelzel M, Hakimi Z, Ridder A, van Maanen R, Stolk EA. Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. *Curr Med Res Opin*. 2016;32(4):787-796. doi:10.1185/03007995.2016.1142959.

Liu FX, **Gao X**, Inglese G, Chuengsaman P, Pecoits-Filho R, Yu A. A global overview of the impact of peritoneal dialysis first or favored policies: an opinion. *Perit Dial Int*. 2015;35(4):406-420. doi:10.3747/pdi.2013.00204.

Thomas JA, Tubaro A, Barber N, Thorpe A, Armstrong N, Bachmann A, **Van Hout B**. The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction. *Value Health*. 2015 Jun;18(4):376-86. doi: 10.1016/j.jval.2015.04.002.

Liu FX, Ghaffari A, **Dhatt H**, Kumar V, Balsera C, Wallace E, Khairullah Q, **Leshner B**, **Gao X**, Henderson H, LaFleur P, Delgado EM, Alvarez MM, Hartley J, McClernon M, Walton S, Guest S. Economic evaluation of urgent-start peritoneal dialysis versus urgent-start hemodialysis in the United States. Khasawneh FT, ed. *Medicine (Baltimore)*. 2014;93(28):e293. doi:10.1097/MD.0000000000000293.

Verheggen BG, Lee R, **Lieuw On MM**, **Treur MJ**, **Botteman MF**, Kaplan SA, Trocio JN. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder. *J Med Econ*. 2012;15(3):586-600. doi:10.3111/13696998.2012.666511.



Schonder KS, **Corman SL**, Hung WY. Early risk factors for persistent anemia after kidney transplantation. *Pharmacotherapy*. 2010;30(12):1214-1220. doi:10.1592/phco.30.12.1214.

Brubaker L, Fanning K, **Goldberg EL**, Benner JS, Trocio JN, Bavendam T, Jumadilova Z. Predictors of discontinuing overactive bladder medications. *BJU Int*. 2010;105(9):1283-1290. doi:10.1111/j.1464-410X.2009.09035.x.

Fourquet J, **Gao X**, Zavala D, Orengo JC, Abac S, Ruiz A, Laboy J, Flores I. Patients' report on how endometriosis affects health, work, and daily life. *Fertil Steril*. 2010;93(7):2424-2428. doi:10.1016/j.fertnstert.2009.09.017.



6 Hematology

Kay G, Eby EL, Brown B, Lyon J, Eggington S, Kumar G, **Fenwick E**, Sohail MR, Wright DJ. Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection. *Journal of Medical Economics*. 2018. 21:3, 294-300, DOI: 10.1080/13696998.2017.1409227

Chuang LH, **van Hout B**, Cohen AT, Gumbs PD, **Kroep S**, Bauersachs R, Gitt A, Monreal M, Willich SN, Agnelli G. Deep-vein thrombosis in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. *Thromb Res*. 2018 Aug 4;170:165-174. doi: 10.1016/j.thromres.2018.08.001. [Epub ahead of print]

Deshpande CG, Kogut S, Willey C. Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy. *J Manag Care Spec Pharm*. 2018 May;24(5):430-439. doi: 10.18553/jmcp.2018.24.5.430.

Horodniceanu EG, Bal V, **Dhatt H**, Carter JA, Huang V, **Lasch K**. Qualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy. *Health Qual Life Outcomes*. 2017 Jun 23;15(1):129. doi: 10.1186/s12955-017-0702-0.

Drummond M, **Houwing N**, Slothuus U, Giangrande P. Making economic evaluations more helpful for treatment choices in haemophilia. *Haemophilia*. 2017;23(2):e58-e66. doi:10.1111/hae.13173.

de Jager T, Pericleous L, Kokot-Kierepa M, Naderi M, Karimi M. The burden and management of FXIII deficiency. *Haemophilia*. 2014;20(6):733-740. doi:10.1111/hae.12474.

Recht M, Neufeld EJ, Sharma VR, **Solem CT**, Pickard AS, Gut RZ, Cooper DL. Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from the Dosing Observational Study in Hemophilia (DOSE). *Value Health*. 2014;17(6):744-748. doi:10.1016/j.jval.2014.07.003.

Neufeld EJ, Recht M, Sabio H, Saxena K, **Solem CT**, Pickard AS, Gut RZ, Cooper DL. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. *Value Health*. 2012;15(6):916-925. doi:10.1016/j.jval.2012.05.005.



Borkent-Raven BA, Janssen MP, van der Poel CL, Bonsel GJ, **van Hout BA**. Cost-effectiveness of additional blood screening tests in the Netherlands. *Transfusion*. 2012;52(3):478-488. doi:10.1111/j.1537-2995.2011.03319.x.

Young G, **Solem CT**, Hoffman K, Kabawat J, Pickard AS, Gut RZ, Cooper DL. Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). *J Blood Med*. 2012;3:131-138. doi:10.2147/JBM.S37016.

Leissinger C, Cooper DL, **Solem CT**; HTRS Investigators. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A. *Haemophilia*. 2011;17(6):884-889. doi:10.1111/j.1365-2516.2011.02509.x.

Neufeld EJ, Kessler CM, Gill JC, **Wilke CT**, Cooper DL; HTRS Investigators. Exposure and safety of higher doses of recombinant factor VIIa ≥ 250 mug kg⁻¹ in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008). *Haemophilia*. 2011;17(4):650-656. doi:10.1111/j.1365-2516.2010.02483.x.

Fischer K, Pouw ME, Lewandowski D, Janssen MP, van den Berg HM, **van Hout BA**. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. *Haematologica*. 2011;96(5):738-743. doi:10.3324/haematol.2010.029868.

Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ, **van Hout BA**. Survival after transfusion in the Netherlands. *Vox Sang*. 2011;100(2):196-203. doi:10.1111/j.1423-0410.2010.01378.x.

Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ, **van Hout BA**. The PROTON study: profiles of blood product transfusion recipients in the Netherlands. *Vox Sang*. 2010;99(1):54-64. doi:10.1111/j.1423-0410.2010.01312.x.
Stephens JM, Joshi AV, Sumner M, **Botteman MF**. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. *Expert Opin Pharmacother*. 2007 Jun;8(8):1127-36.

Liou SY, **Stephens JM**, Carpiuc KT, Feng W, Botteman MF, Hay JW. Economic burden of haematological adverse effects in cancer patients: a systematic review. *Clin Drug Investig*. 2007;27(6):381-96.

van Gestel A, Bakker J, Veraart CP, **van Hout BA**. Prevalence and incidence of severe sepsis in Dutch intensive care units. *Crit Care*. 2004 Aug;8(4):R153-62. *Epub* 2004 May 14.



7 Infectious & Parasitic

Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, **Chatterjee A**, Knight GM, Robotham JV. Estimating the burden of antimicrobial resistance: a systematic literature review. *Antimicrob Resist Infect Control*. 2018 Apr 25;7:58. doi: 10.1186/s13756-018-0336-y. eCollection 2018.

Chatterjee A, Modarai M, Naylor NR, Boyd SE3, Atun R, Barlow J, Holmes AH, Johnson A, Robotham JV. Quantifying drivers of antibiotic resistance in humans: a systematic review. *Lancet Infect Dis*. 2018 Aug 29. pii: S1473-3099(18)30296-2. doi: 10.1016/S1473-3099(18)30296-2. [Epub ahead of print]

Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013-2016. *Adv Ther*. 2018 Jul;35(7):1087-1102. doi: 10.1007/s12325-018-0721-1. Epub 2018 Jun 9.

McKinnell JA, **Corman S**, **Patel D**, Leung GH, Gordon LM, Lodise TP. Effective antimicrobial stewardship strategies for cost-effective utilization of Telavancin for the treatment of patients with hospital-acquired bacterial pneumonia caused by staphylococcus aureus. *Clin. Ther*. 2018 Mar.40(3):406-414.e2. doi: 10.1016/j.clinthera.2018.01.010. Epub 2018 Feb 15.

Lishman H, Aylin P, Alividza V, Castro-Sanchez E, **Chatterjee A**, Mariano V, Johnson AP, Jeraj S, Costelloe C. Investigating the burden of antibiotic resistance in ethnic minority groups in high-income countries: protocol for a systematic review and meta-analysis. *Syst Rev*. 2017 Dec 11;6(1):251. doi: 10.1186/s13643-017-0654-9.

Naylor NR, Uchegbu I, **Chatterjee A**, Robotham JV. Gambling with antibiotics: a novel approach for exploring antibiotic consumption decision-making. *Public Health*. 2017 Oct;151:146-148. doi: 10.1016/j.puhe.2017.07.012. Epub 2017 Aug 9.

Cooke CE, **Stephens JM**. Clinical, economic, and humanistic burden of needlestick injuries in healthcare workers. *Med Devices (Auckl)*. 2017 Sep 29;10:225-235. doi: 10.2147/MDER.S140846.

Corman S, Elbasha EH, **Michalopoulos SN**, Nwankwo C. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. *Value Health*. 2017 Sep;20(8):1110-1120. doi: 10.1016/j.jval.2017.05.003. Epub 2017 Jun 20.

Moghnieh R, Alothman AF, Althaqafi AO, Matar MJ, Alenazi TH, Farahat F, **Corman SL**, **Solem CT**, Raghbir N, Macahilig C, **Stephens JM**. Epidemiology and outcome of invasive fungal infections and methicillin-resistant *Staphylococcus aureus* (MRSA)



pneumonia and complicated skin and soft tissue infections (cSSTI) in Lebanon and Saudi Arabia. *J Infect Public Health*. 2017 May 6. pii: S1876-0341(17)30048-5. doi: 10.1016/j.jiph.2017.01.013.

Alothman AF, Althaqafi AO, Matar MJ, Moghnieh R, Alenazi TH, Farahat FM, **Corman S, Solem CT**, Raghubir N, Macahilig C, Charbonneau C, **Stephens JM**. Burden and treatment patterns of invasive fungal infections in hospitalized patients in the Middle East: real-world data from Saudi Arabia and Lebanon. *Infect Drug Resist*. 2017;10:35-41. doi:10.2147/IDR.S97413.

Matar MJ, Moghnieh R, Alothman AF, Althaqafi AO, Alenazi TH, Farahat FM, **Corman S, Solem CT**, Raghubir N, Macahilig C, Haider S, **Stephens JM**. Treatment patterns, resource utilization, and outcomes among hospitalized patients with methicillin-resistant *Staphylococcus aureus* complicated skin and soft tissue infections in Lebanon and Saudi Arabia. *Infect Drug Resist*. 2017;10:43-48. doi:10.2147/IDR.S97415.

Althaqafi AO, Matar MJ, Moghnieh R, Alothman AF, Alenazi TH, Farahat F, **Corman S, Solem CT**, Raghubir N, Macahilig C, Haider S, **Stephens JM**. Burden of methicillin-resistant *Staphylococcus aureus* pneumonia among hospitalized patients in Lebanon and Saudi Arabia. *Infect Drug Resist*. 2017;10:49-55. doi:10.2147/IDR.S97416.

Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, **Piena MA**, Damele F, Gueron B, **Treur M**, Belsey J. Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service. *Clinicoecon Outcomes Res*. 2017;9:163-172. doi:10.2147/CEOR.S117650.

Mao N, **Leshner B**, Liu Q, Qin L, Chen Y, **Gao X**, Earnshaw SR, McDade CL, Charbonneau C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. *Clinicoecon Outcomes Res*. 2016;8:275-285. doi:10.2147/CEOR.S101015.

Leshner B, Gao X, Chen Y, Liu Z. Methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia: role of linezolid in the People's Republic of China. *Clinicoecon Outcomes Res*. 2016;8:63-72. doi:10.2147/CEOR.S91985.

Charokopou M. Using health economic models to help guide healthcare decisions. *Curr Med Res Opin*. 2016;32(2):205-206. doi:10.1185/03007995.2015.1102721.

Corbacho B, Duarte A, Keding A, Handoll H, **Chuang LH**, Torgerson D, Brealey S, Jefferson L, Hewitt C, Rangan A. Cost effectiveness of surgical versus non-surgical treatment of adults with displaced fractures of the proximal humerus: economic evaluation alongside the PROFHER trial. *Bone Joint J*. February 2016;98-B(2):152-159. doi:10.1302/0301-620X.98B2.36614.



Ektare V, Khachatryan A, Xue M, Dunne M, Johnson K, Stephens J. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. *J Med Econ.* 2015;18(12):1092-1101. doi:10.3111/13696998.2015.1078339.

Kaye KS, **Patel DA, Stephens JM, Khachatryan A, Patel A, Johnson K.** Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact. *PLoS One.* 2015;10(11):e0143276. doi:10.1371/journal.pone.0143276.

Leshner BA, Liu Z, Chen Y, Gao X. Linezolid for the treatment of hospital-acquired pneumonia in a Chinese tertiary hospital. *Clinicoecon Outcomes Res.* 2015;7:521-526. doi:10.2147/CEOR.S89570.

Eckmann C, Nathwani D, Lawson W, **Corman S, Solem C, Stephens J, Macahilig C, Li J, Charbonneau C, Baillon-Plot N, Haider S.** Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated skin and soft-tissue infections due to methicillin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect.* 2015;21(suppl 2):S33-S39. doi:10.1016/j.cmi.2015.01.011.

Dryden M, Baguneid M, Eckmann C, **Corman S, Stephens J, Solem C, Li J, Charbonneau C, Baillon-Plot N, Haider S.** Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections. *Clin Microbiol Infect.* 2015;21(suppl 2):S27-S32. doi:10.1016/j.cmi.2015.03.024.

Lawson W, Nathwani D, Eckmann C, **Corman S, Stephens J, Solem C, Macahilig C, Li J, Baillon-Plot N, Charbonneau C, Haider S.** Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect.* 2015;21(suppl 2):S40-S46. doi:10.1016/j.cmi.2015.05.030.

Nathwani D, Lawson W, Dryden M, **Stephens J, Corman S, Solem C, Li J, Charbonneau C, Baillon-Plot N, Haider S, Eckmann C.** Implementing criteria-based early switch/early discharge programmes: a European perspective. *Clin Microbiol Infect.* 2015;21(suppl 2):S47-S55. doi:10.1016/j.cmi.2015.03.023.

El Houfi A, Javed N, **Solem CT, Macahilig C, Stephens JM, Raghubir N, Chambers R, Li JZ, Haider S.** Early-switch/early-discharge opportunities for hospitalized patients with methicillin-resistant *Staphylococcus aureus* complicated skin and soft tissue infections: proof of concept in the United Arab Emirates. *Infect Drug Resist.* 2015;8:173-179. doi:10.2147/IDR.S78786.



Westerhout K, Treur M, Mehnert A, Pascoe K, Ladha I, Belsey J. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. *J Med Econ.* 2015;18(10):838-849. doi:10.3111/13696998.2015.1044457.

Kuwabara H, **Westerhout K, Treur M**, Cerri K, Mahlich J, Yatsuhashi H. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan. *J Med Econ.* 2015;18(7):502-511. doi:10.3111/13696998.2015.1029492.

Niederman MS, Chastre J, **Solem CT, Wan Y, Gao X**, Myers DE, Haider S, Li JZ, **Stephens JM**. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus*: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid. *Clin Ther.* 2014;36(9):1233-1243. doi:10.1016/j.clinthera.2014.06.029.

Nathwani D, Eckmann C, Lawson W, **Stephens JM**, Macahilig C, **Solem CT**, Simoneau D, Chambers R, Li JZ, Haider S. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant *Staphylococcus aureus* complicated skin and soft tissue infections. *Clin Microbiol Infect.* 2014;20(10):993-1000. doi:10.1111/1469-0691.12632.

Patel DA, Michel A, **Stephens J**, Weber B, Petrik C, Charbonneau C. An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia in Germany. *Infect Drug Resist.* 2014;7:273-280. doi:10.2147/IDR.S68658.

Nathwani D, Eckmann C, Lawson W, **Solem CT, Corman S, Stephens JM**, Macahilig C, Simoneau D, Chambers R, Li JZ, Haider S. Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe. *BMC Infect Dis.* 2014;14:476. doi:10.1186/1471-2334-14-476.

Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, **Stephens J**, Nichols G. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naïve HIV-1-infected patients: a systematic review and network meta-analysis. *PLoS One.* 2014;9(9):e105653. doi:10.1371/journal.pone.0105653.

Ostermann H, Solano C, Jarque I, Garcia-Vidal C, **Gao X**, Barrueta JA, De Salas-Cansado M, **Stephens J, Xue M**, Weber B, Charbonneau C. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. *BMC Pharmacol Toxicol.* 2014;15:52. doi:10.1186/2050-6511-15-52.



Snedecor SJ, Sudharshan L, Nedrow K, Bhanegaonkar A, Simpson KN, Haider S, Chambers R, Craig C, Stephens J. Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. *AIDS Res Hum Retroviruses*. 2014;30(8):753-768. doi:10.1089/AID.2013.0262.

Eckmann C, Lawson W, Nathwani D, **Solem CT, Stephens JM**, Macahilig C, Simoneau D, Hajek P, Charbonneau C, Chambers R, Li JZ, Haider S. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to methicillin-resistant *Staphylococcus aureus*: a plea for implementation of early switch and early discharge criteria. *Int J Antimicrob Agents*. 2014;44(1):56-64. doi:10.1016/j.ijantimicag.2014.04.007.

Tan SC, Wang X, Wu B, Kang H, Li Q, Chen Y, Chen C, Hajek P, **Patel DA, Gao X.** Cost-effectiveness of linezolid versus vancomycin among patients with methicillin-resistant *Staphylococcus aureus* confirmed nosocomial pneumonia in China. *Value Health Reg Issues*. 2014;3:94-100. doi:10.1016/j.vhri.2014.03.002.

Solem CT, Snedecor SJ, Khachatryan A, Nedrow K, Tawadrous M, Chambers R, Haider S, Simpson K. Cost of treatment in a US commercially insured, HIV-1-infected population. *PLoS One*. 2014;9(5):e98152. doi:10.1371/journal.pone.0098152.

Drgona L, **Khachatryan A, Stephens J**, Charbonneau C, Kantecki M, Haider S, Barnes R. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of *Aspergillus* and *Candida* species. *Eur J Clin Microbiol Infect Dis*. 2014;33(1):7-21. doi:10.1007/s10096-013-1944-3.

Stephens J, Gao X, Patel D, Verheggen BG, Shelbaya A, Haider S. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant *Staphylococcus aureus* complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. *Clinicoecon Outcomes Res*. 2013;5:447-457. doi:10.2147/CEOR.S46991.

Gao X, Marks DI, Schlamm HT, Ji X, Stephens JM, Tarallo M. Association between drug tolerability and medical resource use in prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplant. *J Med Econ*. 2013;16(8):1061-1070. doi:10.3111/13696998.2013.811078.

Snedecor SJ, Khachatryan A, Nedrow K, Chambers R, Li C, Haider S, Stephens J. The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients. *PLoS One*. 2013;8(8):e72784. doi:10.1371/journal.pone.0072784.

Wu AW, Hanson KA, Harding G, Haider S, Tawadrous M, **Khachatryan A**, Pashos CL, Simpson KN. Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults



receiving antiretroviral therapies. *Health Qual Life Outcomes*. 2013;11:42.
doi:10.1186/1477-7525-11-42.

Baddley JW, **Stephens JM**, **Ji X**, **Gao X**, Schlamm HT, Tarallo M. Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes. *BMC Infect Dis*. 2013;13:29. doi:10.1186/1471-2334-13-29.

Gao X, **Stephens JM**, **Carter JA**, Haider S, Rustgi VK. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. *Expert Rev Pharmacoecon Outcomes Res*. 2012;12(3):335-343.
doi:10.1586/erp.12.10.

Wiegand PN, Nathwani D, Wilcox MH, **Stephens J**, Shelbaya A, Haider S. Clinical and economic burden of *Clostridium difficile* infection in Europe: a systematic review of healthcare-facility-acquired infection. *J Hosp Infect*. 2012;81(1):1-14.
doi:10.1016/j.jhin.2012.02.004.

Thureson PO, **Heeg B**, Lescrauwaet B, Sennfält K, Alaeus A, Neubauer A. Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden. *Scand J Infect Dis*. 2011;43(4):304-312. doi:10.3109/00365548.2010.545835.

Patel DA, **Gao X**, **Stephens JM**, Forshag MS, Tarallo M. US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host. *J Med Econ*. 2011;14(2):227-237. doi:10.3111/13696998.2011.564246.

Idema WJ, **Majer IM**, Pahan D, Oskam L, Polinder S, Richardus JH. Cost-effectiveness of a chemoprophylactic intervention with single dose rifampicin in contacts of new leprosy patients. *PLoS Negl Trop Dis*. 2010;4(11):e874. doi:10.1371/journal.pntd.0000874.

Logman JF, **Stephens J**, **Heeg B**, Haider S, Cappelleri J, Nathwani D, Tice A, **van Hout BA**. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. *Curr Med Res Opin*. 2010;26(7):1565-1578. doi:10.1185/03007995.2010.481251.

Wassenberg MW, de Wit GA, **van Hout BA**, Bonten MJ. Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: the case of MRSA. *PLoS One*. 2010;5(7):e11562. doi:10.1371/journal.pone.0011562.



8 Musculoskeletal

Shelbaya A, **Solem CT**, Walker C, Wan Y, Johnson C, Cappelleri JC. The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis. *Clinicoecon. Outcomes Res.* 2018 Apr 6;10:213-222. doi: 10.2147/CEOR.S140208. eCollection 2018.

Corman S, Shah N, Dagenais S. Medication, equipment, and supply costs for common interventions providing extended post-surgical analgesia following total knee arthroplasty in US hospitals. *J Med Econ.* 2018 Jan;21(1):11-18. doi: 10.1080/13696998.2017.1371031. Epub 2017 Sep 18.

Wilke T, Mueller S, Lee SC, **Majer I**, **Heisen M**. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. *BMC Musculoskelet Disord.* 2017 Aug 2;18(1):332. doi: 10.1186/s12891-017-1684-0.

Aletaha D, **Snedecor SJ**, **Ektare V**, **Xue M**, Bao Y, Garg V. Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor- α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. *Clinicoecon Outcomes Res.* 2017 Jul 28;9:451-458. doi: 10.2147/CEOR.S136327. eCollection 2017.

Atzinger CB, Guo JJ. Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends. *Am Health Drug Benefits.* 2017 Feb;10(1):27-36.

Corbacho B, Duarte A, Keding A, Handoll H, **Chuang LH**, Torgerson D, Brealey S, Jefferson L, Hewitt C, Rangan A. Cost effectiveness of surgical versus non-surgical treatment of adults with displaced fractures of the proximal humerus: economic evaluation alongside the PROFHER trial. *Bone Joint J.* 2016;98-B(2):152-159. doi:10.1302/0301-620X.98B2.36614.

Emery P, **Solem C**, **Majer I**, Cappelleri JC, Tarallo M. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. *Rheumatol Int.* 2015;35(11):1837-1849. doi:10.1007/s00296-015-3312-3.

Pierotti F, Palla I, **Treur M**, Pippo L, Turchetti G. Assessment of the economic impact of belimumab for the treatment of systemic lupus erythematosus in the Italian setting: a cost-effectiveness analysis. *PLoS One.* 2015;10(10):e0140843. doi:10.1371/journal.pone.0140843.



Moots RJ, **Mays R**, **Stephens J**, Tarallo M. Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs. *Clin Exp Rheumatol*. 2015;33(5):737-745.

Bruce I, Harman N, Williamson P, Tierney S, Callery P, Mohiuddin S, Payne K, **Fenwick E**, Kirkham J, O'Brien K. The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. *Health Technol Assess*. 2015, 19 (68): 1-374.

Mohiuddin S, Payne K, **Fenwick E**, O'Brien K, Bruce I. A model-based cost-effectiveness analysis of a grommets-led care pathway for children with cleft palate affected by otitis media with effusion. *The European Journal of Health Economics*. 2015, 16 (6): 573-587.

Stephens S, **Botteman MF**, Cifaldi MA, **van Hout BA**. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. *BMJ Open*. 2015;5(6):e006560. doi:10.1136/bmjopen-2014-006560.

Handoll H, Brealey S, Rangan A, Keding A, Corbacho B, Jefferson L, **Chuang LH**, Goodchild L, Hewitt C, Torgerson D. The PROFHER (Proximal Fracture of the Humerus: Evaluation by Randomisation) trial - a pragmatic multicentre randomised controlled trial evaluating the clinical effectiveness and cost-effectiveness of surgical compared with non-surgical treatment for proximal fracture of the humerus in adults. *Health Technol Assess*. 2015;19(24):1-280. doi:10.3310/hta19240.

Rangan A, Handoll H, Brealey S, Jefferson L, Keding A, Martin BC, Goodchild L, **Chuang LH**, Hewitt C, Torgerson D; PROFHER Trial Collaborators. Surgical vs nonsurgical treatment of adults with displaced fractures of the proximal humerus: the PROFHER randomized clinical trial. *JAMA*. 2015;313(10):1037-1047. doi:10.1001/jama.2015.1629.

Snedecor SJ, **Sudharshan L**, Cappelleri JC, Sadosky A, Desai P, Jalundhwala Y, **Botteman M**. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. *Int J Clin Pract*. 2014;68(7):900-918. doi:10.1111/ijcp.12411.

Gu NY, **Botteman MF**, Gerber RA, **Ji X**, **Postema R**, **Wan Y**, Sianos G, Anthony I, Cappelleri JC, Szczypa P, **van Hout B**. Eliciting health state utilities for Dupuytren's contracture using discrete choice experiments (DCE). *Acta Orthop*. 2013;84(6):571-578. doi:10.3109/17453674.2013.865097.

Jolly M, Pickard AS, Sequeira W, Wallace DJ, **Solem CT**, Mikolaitis RA, Fogg L, Weisman MH, Block JA, Cash TF. A brief assessment tool for body image in systemic



lupus erythematosus. *Body Image*. 2012;9(2):279-284.
doi:10.1016/j.bodyim.2011.11.001.

Gao X, Wendling D, **Botteman MF**, **Carter JA**, Rao S, Cifaldi M. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. *J Med Econ*. 2012;15(6):1054-1063.
doi:10.3111/13696998.2012.692341.

Kluza E, **Heisen M**, Schmid S, van der Schaft DW, Schiffelers RM, Storm G, ter Haar Romeny BM, Strijkers GJ, Nicolay K. Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. *Angiogenesis*. 2011;14(2):143-153.
doi:10.1007/s10456-010-9198-5.

Farooq U, Guo X, **Chuang LH**, Fang H, Zhuang G, Xia C. Measuring health-related quality of life in Kashin-Beck disease using EQ-5D. *Qual Life Res*. 2011;20(3):425-429. doi:10.1007/s11136-010-9820-4.

Terwee CB, **Bouwmeester W**, van Elsland SL, de Vet HCW, Dekker J. Instruments to assess physical activity in patients with osteoarthritis of the hip or knee: a systematic review of measurement properties. *Osteoarthritis Cartilage*. 2011;19(6):620-633.
doi:10.1016/j.joca.2011.01.002.

Cummins E, Asseburg C, Puneekar Y, Shore E, Morris J, Briggs A, **Fenwick E**. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. *Value in Health*. 2011, 14 (1): 15-23. ISSN 1098-3015.

Gu NY, Huang X, Fox KM, Patel V, Baumgartner S, Chiou CF. Claims data analysis of dosing and cost of TNF antagonists in rheumatoid arthritis. *Am J Pharm Benefits*. 2010;2(6):351-359.

Huang X, **Gu NY**, Fox KM, Harrison DJ, Globe D. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. *Curr Med Res Opin*. 2010;26(7):1637-1645. doi:10.1185/03007995.2010.483127.

Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL, **van Hout BA**. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. *Rheumatology (Oxford)*. 2007 Aug;46(8):1320-8. Epub 2007 Jun 2



9 Oncology

McDermott DF, **Shah R**, Gupte-Singh K, Sabater J, **Luo L**, **Botteman M**, Rao S, Regan MM, Atkins M. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. *Qual Life Res.* 2018 Sep 6. doi: 10.1007/s11136-018-1984-3. [Epub ahead of print]

Joshi N, **Hensen M**, **Patel S**, **Xu W**, **Lasch K**, Stolk E. Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study. *Pharmacoeconomics.* 2018 Aug 23. doi: 10.1007/s40273-018-0704-8. [Epub ahead of print]

Shi G, Park SH, Ren H, Xue M, Lu X, Dong P, **Gao X**. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China. *J Med Econ.* 2018 Sep 10:1-9. doi: 10.1080/13696998.2018.1515769. [Epub ahead of print]

Cheung WY, White MK, Bayliss MS, **Stroupe A**, Lovley A, **King-Kallimanis BL**, **Lasch K**. Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada. *Support Care Cancer.* 2018 Jun 23. doi: 10.1007/s00520-018-4316-9. [Epub ahead of print]

Young R, Mainwaring P, Clingan P, Parnis FX, Asghari G, Beale P, **Aly A**, **Botteman M**, Romano A, Ferrara S, Margunato-Debay S, Harris M. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. *Asia Pac J Clin Oncol.* 2018 Jun 22. doi: 10.1111/ajco.12999. [Epub ahead of print]

Chiorean EG, Von Hoff D, Wan Y, Margunato-Debay S, **Botteman M**, Goldstein D. Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. *Cancer Manag Res.* 2018 May 31;10:1389-1396. doi: 10.2147/CMAR.S163475. eCollection 2018.

Hirsh V, Wan Y, Lin FJ, Margunato-Debay S, Ong TJ, **Botteman M**, Langer C. Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin. *Clin Lung Cancer.* 2018 Sep;19(5):401-409.e4. doi: 10.1016/j.clcc.2018.04.023. Epub 2018 May 7.

Hájek R, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora 9, Fraňková H, Campioni M, DeCosta L, **Treur M**, Gonzalez-McQuire S, **Bouwmeester W**. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis



of the Czech Registry of Monoclonal Gammopathies. *Clin Lymphoma Myeloma Leuk*. 2018 Jun;18(6):e219-e240. doi: 10.1016/j.clml.2018.04.003. Epub 2018 Apr 17.

Cortes J, Pérez-García J, Whiting S, **Wan Y**, **Solem C**, Tai MH, Margunato-Debay S, Ko A, Fandi A, **Botteman M**. Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis. *Clin Breast Cancer*. 2018 Mar 30. pii: S1526-8209(17)30778-4. doi: 10.1016/j.clbc.2018.03.014. [Epub ahead of print]

Solem CT, Kwon Y, **Shah RM**, **Aly A**, **Botteman MF**. Systematic review and benchmarking of quality-adjusted time without symptoms or toxicity (Q-TWiST) in oncology. *Expert Rev Pharmacoecon Outcomes Res*. 2018 Jun;18(3):245-253. doi: 10.1080/14737167.2018.1434414. Epub 2018 Feb 5.

Cheung WY, Bayliss MS, White MK, **Stroupe A**, Lovley A, **King-Kallimanis BL**, **Lasch K**. Humanistic burden of disease for patients with advanced melanoma in Canada. *Support Care Cancer*. 2018 Jun;26(6):1985-1991. doi: 10.1007/s00520-017-4025-9. Epub 2018 Jan 10.

Zagadailov EA, **Corman S**, **Chirikov V**, **Johnson C**, Macahilig C, Seal B, Dalal MR, Bröckelmann PJ, Illidge T. Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. *Leuk Lymphoma*. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1382698

Bröckelmann PJ, Zagadailov EA, **Corman SL**, **Chirikov V**, **Johnson C**, Macahilig C, Seal B, Dalal MR, Illidge T. Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma who are Ineligible for Autologous Stem Cell Transplant: A Germany and UK Retrospective Study. *Eur J Haematol*. 2017 Sep 26. doi: 10.1111/ejh.12973

Jiang S, Hill K, **Patel D**, Waldeck AR, **Botteman M**, **Aly A**, Norden AD. Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients. *J Med Econ*. 2017 Dec;20(12):1237-1243. doi: 10.1080/13696998.2017.1364258. Epub 2017 Aug 16.

Keeping ST, **Tempest MJ**, **Stephens SJ**, Carroll SM, Simcock R, Jones TM, Shaw R. The Cost of Oropharyngeal Cancer in England: a Retrospective Hospital Data Analysis. *Clin Otolaryngol*. 2018 Feb;43(1):223-229. doi: 10.1111/coa.12944. Epub 2017 Aug 14.

Deshmukh AA, Cantor SB, **Fenwick E**, Chiao EY, Nyitray AG, Stier EA, Goldstone SE, Wilkin T, Chhatwal J. Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now. *Vaccine*. 2017. 12;35 (38): 5102-9.



Waldeck AR, **Botteman MF**, White RE, **van Hout BA**. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making. *J Manag Care Spec Pharm*. 2017 Jun;23(6-a Suppl):S6-S12. doi: 10.18553/jmcp.2017.23.6-a.s6.

Pelzer U, Blanc J, Melisi D3, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, **Wan Y**, **Solem CT**, **Botteman MF**, Yang Y, de Jong FA, Hubner RA. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. *Br J Cancer*. 2017 May 9;116(10):1247-1253. doi: 10.1038/bjc.2017.67.

Tsai CF, Tsai PS, Liu CL, Lin YK, **Ling YL**, Tseng IJ, Liao YM. Psychometric Evaluation of the Chinese Breast Cancer Prevention Trial Symptom Scale. *Cancer Nurs*. 2017 May 5. doi: 10.1097/NCC.0000000000000499.

Flannery K, Drea E, Hudspeth L, **Corman S**, **Gao X**, **Xue M**, Miao R. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer. *J Manag Care Spec Pharm*. 2017 Apr;23(4):416-426.

Majer I, **van de Wetering G**, Polanyi Z, Krishna A, Gray E, Roy A. Panobinostat plus bortezomib versus lenalidomide in patients with relapsed and/or refractory multiple myeloma: a matching-adjusted indirect treatment comparison of survival outcomes using patient-level data. *Appl Health Econ Health Policy*. 2017;15(1):45-55. doi:10.1007/s40258-016-0271-0.

Vogel A, Ciardiello F, Hubner RA, Blanc JF, Carrato A, Yang Y, **Patel DA**, **Ektare V**, de Jong FA, Gill S. Post-gemcitabine therapy for patients with advanced pancreatic cancer – a comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. *Cancer Treat Rev*. 2016;50:142-147. doi:10.1016/j.ctrv.2016.09.001.

Mercieca-Bebber RL, Perreca A, King M, Macann A, Whale K, Soldati S, **Jacobs M**, Efficace F. Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: a systematic review of completeness of reporting and impact on interpretation. *Eur J Cancer*. 2016;56:144-161. doi:10.1016/j.ejca.2015.12.025.

Zeidan AM, Mahmoud D, **Kucmin-Bemelmans IT**, **Alleman CJ**, **Hensen M**, Skikne B, Smith BD. Economic burden associated with acute myeloid leukemia treatment. *Expert Rev Hematol*. 2016;9(1):79-89. doi:10.1586/17474086.2016.1112735.

Howlett C, **Snedecor SJ**, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free



survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. *Br J Haematol.* 2015;170(4):504-514. doi:10.1111/bjh.13463.

Keeping ST, **Tempest MJ**, **Stephens SJ**, **Carroll SM**, Sangar VK. Penile cancer treatment costs in England. *BMC Public Health.* 2015;15:1305. doi:10.1186/s12889-015-2669-2.

Langer CJ, Hirsh V, Okamoto I, **Lin FJ**, **Wan Y**, Whiting S, Ong TJ, Renschler MF, **Botteman MF**. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. *Br J Cancer.* 2015;113(1):20-29. doi:10.1038/bjc.2015.181.

Keeping ST, **Tempest MJ**, **Stephens SJ**, Carroll SM, Nugent KP, O'Dwyer ST. The cost of anal cancer in England: retrospective hospital data analysis and Markov model. *BMC Public Health.* 2014;14:1123. doi:10.1186/1471-2458-14-1123.

Reni M, **Wan Y**, **Solem C**, Whiting S, **Ji X**, **Botteman M**. Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. *J Med Econ.* 2014;17(5):338-346. doi:10.3111/13696998.2014.903122.

Noens L, **Hensen M**, **Kucmin-Bemelmans I**, Lofgren C, Gilloteau I, Vrijens B. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. *Haematologica.* 2014;99(3):437-447. doi:10.3324/haematol.2012.082511.

Bennison C, **Stephens S**, Conti NC. Cost-effectiveness analysis of hexaminolevulinat (Hexvix[®]) guided cystoscopy in non-muscle invasive bladder cancer patients (NMIBC) in Italy. *Farmeconomia Percorsi Ter.* 2014;15(3). doi:10.7175/fe.v15i3.944.

Hillen MA, Koning CCE, Wilmlink JW, Klinkenbijn JHG, Eddes EH, **King-Kallimanis BL**, de Haes JCJM, Smets EMA. Assessing cancer patients' trust in their oncologist: development and validation of the Trust in Oncologist Scale (TiOS). *Support Care Cancer.* 2014;20(8):1781-1795. doi:10.1007/2Fs00520-011-1276-8.

Wan Y, **Gao X**, **Mehta S**, Wang Z, Faria C, Schwartzberg L. Indirect costs associated with metastatic breast cancer. *J Med Econ.* 2013;16(10):1169-1178. doi:10.3111/13696998.2013.826228.

Majer IM, Gelderblom H, van den Hout WB, Gray E, **Verheggen BG**. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial. *J Med Econ.* 2013;16(9):1106-1119. doi:10.3111/13696998.2013.819357.



Carter JA, Ji X, Botteman MF. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. *Expert Rev Pharmacoecon Outcomes Res.* 2013;13(4):483-496. doi:10.1586/14737167.2013.820959.

Tong WH, van der Sluis IM, **Alleman C**, van Litsenburg RR, Kaspers G, Pieters R, Uyl-de Groot CA. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy. *Haematologica.* 2013;98(5):753-759. doi:10.3324/haematol.2012.073510.

Ganguli A, **Wiegand P, Gao X, Carter JA, Botteman MF**, Ray S. The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review. *Qual Life Res.* 2013;22(5):1015-1026. doi:10.1007/s11136-012-0229-0.

Snedecor SJ, Carter JA, Kaura S, **Botteman MF.** Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. *J Med Econ.* 2013;16(1):19-29. doi:10.3111/13696998.2012.719054.

Carter JA, Botteman MF. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. *Expert Rev Pharmacoecon Outcomes Res.* 2012;12(4):425-437. doi:10.1586/erp.12.31.

Snedecor SJ, Carter JA, Kaura S, **Botteman MF.** Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer. *Clin Ther.* 2012;34(6):1334-1349. doi:10.1016/j.clinthera.2012.04.008.

Carter JA, Joshi AD, Kaura S, **Botteman MF.** Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. *Pharmacoeconomics.* 2012;30(5):373-386. doi:10.2165/11631390-000000000-00000.

Botteman MF, Meijboom M, Foley I, **Stephens JM**, Chen YM, Kaura S. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. *Eur J Health Econ.* 2011;12(6):575-588. doi:10.1007/s10198-010-0272-0.

Yu XM, **Wan Y**, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. *Ann Surg.* 2011;254(4):653-660. doi:10.1097/SLA.0b013e318230036d.



Scott JA, **Lasch KE**, Barsevick AM, Piauxt-Louis E. Patients' experiences with cancer-related fatigue: a review and synthesis of qualitative research. *Oncol Nurs Forum*. 2011;38(3):E191-203. doi:10.1188/11.ONF.E191-E203.

Joshi AD, Carter JA, Botteman MF, Kaura S. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United Kingdom. *Clin Ther*. 2011;33(3):291-304. doi:10.1016/j.clinthera.2011.04.002.

Carter JA, Joshi A, Kaura S, **Botteman MF**. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. *J Med Econ*. 2011;14(3):288-298. doi:10.3111/13696998.2011.570170

Brush J, Boyd K, Chappell F, Crawford F, Dozier M, **Fenwick E**, Glanville J, McIntosh H, Renehan A, Weller D and Dunlop MG. The value of positron emission tomography-computerised tomography (18FDG PET-CT) in pre-operative staging of colorectal cancer. *Health Technol Assess*. 2011, 15 (35): 1-192. ISSN 1366-5278.

Carpuc KT, Rosti G, Castagnetti F, **Treur M, Stephens J**. Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics. *Onco Targets Ther*. 2010;3:205-210. doi:10.2147/OTT.S13052.

Lang HC, **Chuang L**, Shun SC, Hsieh CL, Lan CF. Validation of EQ-5D in patients with cervical cancer in Taiwan. *Support Care Cancer*. 2010;18(10):1279-1286. doi:10.1007/s00520-009-0745-9.

Heisen M, Fan X, Buurman J, van Riel NA, Karczmar GS, ter Haar Romeny BM. The use of a reference tissue arterial input function with low-temporal-resolution DCE-MRI data. *Phys Med Biol*. 2010;55(16):4871-4883. doi:10.1088/0031-9155/55/16/016.

Logman JF, Heeg BM, Botteman MF, Kaura S, **van Hout BA**. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. *Ann Oncol*. 2010;21(7):1529-1536. doi:10.1093/annonc/mdp560.

Stephens J, Carpiuc KT, Botteman M. The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis. *Int J Gen Med*. 2010;3:31-36.

Heisen M, Fan X, Buurman J, van Riel NA, Karczmar GS, ter Haar Romeny BM. The influence of temporal resolution in determining pharmacokinetic parameters from DCE-MRI data. *Magn Reson Med*. 2010;63(3):811-816. doi:10.1002/mrm.22171.



Lasch K, Stokes J, Liepa AM, Meldahl M, Arnett L, Basch E. Drivers of treatment decision following first-line therapy in advanced non-small cell lung cancer. *Support Care Cancer*. 2010;18(suppl 3):S88-S89.

Logman JF, **Heeg BM**, **Botteman MF**, Kaura S, **van Hout BA**. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. *Ann Oncol*. 2010 Jul;21(7):1529-36. doi: 10.1093/annonc/mdp560. Epub 2009 Dec 2.

Hoomans T, **Fenwick E**, Palmer S, Claxton K. Value of information and value of implementation: Application of an analytical framework to inform resource allocation decisions in Metastatic Hormone-Refractory Prostate Cancer. *Value in Health*. 2009, 12 (2): 315-324. ISSN 10983015

Carpuc KT, **Stephens JM**, **Botteman MF**, Feng W, Hay JW. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. *Expert Opin Pharmacother*. 2007 Nov;8(16):2775-87.

Liou SY, **Stephens JM**, Carpiuc KT, Feng W, Botteman MF, Hay JW. Economic burden of haematological adverse effects in cancer patients: a systematic review. *Clin Drug Investig*. 2007;27(6):381-96.

Botteman M, Barghout V, Stephens J, Hay J, Brandman J, Aapro M. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. *Ann Oncol*. 2006 Jul;17(7):1072-82. Epub 2006 May 2.

Collins R, **Fenwick E**, Trowman R, Perard R, Norman G, Light K, Birtle A, S Palmer and R Riemsma. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. *Health Technol Assess*. 2007, 11: 1-179.

Collins R, Trowman R, Norman G, Light G, Birtle A, **Fenwick E**, Palmer S and Riemsma R. **A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer**. *British Journal of Cancer*. 2006, 95: 457-462.



10 Orphan Drugs

Solem CT, Vera-Llonch M, **Liu S**, **Botteman MF**, **Lasch K**, Rodriguez S, Castiglione B. Responsiveness of the EQ-5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. *Value Health*. 2014;17(3):A178. doi:10.1016/j.jval.2014.03.1038.

Carpic KT, Rosti G, Castagnetti F, **Treur M**, **Stephens J**. Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics. *Onco Targets Ther*. 2010;3:205-210. doi:10.2147/OTT.S13052.

Stephens J, **Carpic KT**, **Botteman M**. The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis. *Int J Gen Med*. 2010;3:31-36.



11 Pain

Marcus J, **Lasch K**, **Wan Y**, Yang M, Hsu C, Merante D. An Assessment of Clinically Important Differences on the Worst Pain Severity Item of the Modified Brief Pain Inventory in Patients with Diabetic Peripheral Neuropathic Pain. *Pain Res Manag.* 2018 Jul 22;2018:2140420. doi: 10.1155/2018/2140420. eCollection 2018.

van Nooten F, **Treur M**, **Pantiri K**, Stoker M, **Charokopou M**. Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis. *Clin Ther.* 2017 Apr;39(4):787-803.e18. doi: 10.1016/j.clinthera.2017.02.010.

Joshi G, Gandhi K, Shah N, Gadsden J, **Corman SL**. Peripheral nerve blocks in the management of postoperative pain: challenges and opportunities. *J Clin Anesth.* 2016;35:524-529. doi:10.1016/j.jclinane.2016.08.041.

Alleman CJ, **Westerhout KY**, **Hensen M**, Chambers C, Stoker M, Long S, van Nooten FE. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature. *Diabetes Res Clin Pract.* 2015;109(2):215-225. doi:10.1016/j.diabres.2015.04.031.

Snedecor SJ, **Sudharshan L**, Cappelleri JC, Sadosky A, Desai P, Jalundhwala Y, **Botteman M**. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. *Int J Clin Pract.* 2014;68(7):900-918. doi:10.1111/ijcp.12411.

Palmer P, **Ji X**, **Stephens J**. Cost of opioid intravenous patient-controlled analgesia: results from a hospital database analysis and literature assessment. *Clinicoecon Outcomes Res.* 2014;6:311-318. doi:10.2147/CEOR.S64077.

Snedecor SJ, **Sudharshan L**, Cappelleri JC, Sadosky A, **Mehta S**, **Botteman M**. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. *Pain Pract.* 2014;14(2):167-184. doi:10.1111/papr.12054.

Snedecor SJ, **Sudharshan L**, Cappelleri JC, Sadosky A, Desai P, Jalundhwala YJ, **Botteman M**. Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury. *J Pain Res.* 2013;6:539-547. doi:10.2147/JPR.S45966.

Chuang LH, Soares MO, Tilbrook H, Cox H, Hewitt CE, Aplin J, Semlyen A, Trehwela A, Watt I, Torgerson DJ. A pragmatic multicentered randomized controlled trial of yoga for chronic low back pain: economic evaluation. *Spine (Phila Pa 1976).* 2012;37(18):1593-1601. doi:10.1097/BRS.0b013e3182545937.



Gu NY, Bell C, **Botteman MF**, **Ji X**, **Carter JA**, **van Hout B**. Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores. *Patient*. 2012;5(3):185-197. doi:10.2165/11630970-000000000-00000.

Cox H, Tilbrook H, Aplin J, **Chuang LH**, Hewitt C, Jayakody S, Semlyen A, Soares MO, Torgerson D, Trehwela A, Watt I, Worthy G. A pragmatic multi-centred randomised controlled trial of yoga for chronic low back pain: trial protocol. *Complement Ther Clin Pract*. 2010 May;16(2):76-80. doi:10.1016/j.ctcp.2009.09.010.

Gu NY, Bell C, **Botteman M**, **van Hout B**. Association between self-reported neuropathic pain severity and the EQ-5D in patients with painful diabetic peripheral neuropathy (pDPN) or post-herpetic neuralgia (PHN). *Value Health*. 2010;13(3):A213. doi:10.1016/S1098-3015(10)73044-8.

Gu NY, Bell C, **Botteman M**, **van Hout B**. Comparing the time tradeoff (TTO), the visual analogue scale (VAS) and the EQ-5D value-sets in patients treated with painful diabetic peripheral neuropathy (pDPN) or post-herpetic neuralgia (PHN). *Value Health*. 2010;13(3):A212. doi:10.1016/S1098-3015(10)73039-4.



12 Respiratory

Willich SN, Chuang LH, **van Hout B**, Gumbs P, Jimenez D, **Kroep S**, Bauersachs R, Monreal M, Agnelli G, Cohen A. Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. *Thromb Res*. 2018 Feb 16;170:181-191. doi: 10.1016/j.thromres.2018.02.009. [Epub ahead of print]

McKinnell JA, **Corman S**, **Patel D**, Leung GH, Gordon LM, Lodise TP. Effective antimicrobial stewardship strategies for cost-effective utilization of Telavancin for the treatment of patients with hospital-acquired bacterial pneumonia caused by staphylococcus aureus. *Clin. Ther*. 2018 Mar.40(3):406-414.e2. doi: 10.1016/j.clinthera.2018.01.010. Epub 2018 Feb 15.

Rello J, Nieto M, Solé-Violán J, **Wan Y**, **Gao X**, **Solem CT**, De Salas-Cansado M, Mesa F, Charbonneau C, Chastre J. Nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus* treated with linezolid or vancomycin: a secondary economic analysis of resource use from a Spanish perspective. *Med Intensiva*. 2016;40(8):474-482. doi:10.1016/j.medin.2016.01.007.

Solem CT, Vera-Llonch M, **Liu S**, **Botteman M**, Castiglione B. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. *Health Qual Life Outcomes*. 2016;14:63. doi:10.1186/s12955-016-0465-z.

Leshner B, **Gao X**, Chen Y, Liu Z. Methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia: role of linezolid in the People's Republic of China. *Clinicoecon Outcomes Res*. 2016;8:63-72. doi:10.2147/CEOR.S91985.

Wan Y, Li Q, Chen Y, Haider S, **Liu S**, **Gao X**. Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus* and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a phase 4 clinical trial study. *J Med Econ*. 2016;19(1):53-62. doi:10.3111/13696998.2015.1088448.

Wan Y, Sun SX, **Corman S**, Huang X, **Gao X**, Shorr AF. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world. *Int J Chron Obstruct Pulmon Dis*. 2015;10:2127-2136. doi:10.2147/COPD.S80106.

Verheggen BG, **Westerhout KY**, Schreder CH, Augustin M. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. *Clin Transl Allergy*. 2015;5(1):1. doi:10.1186/s13601-015-0045-z.



Solem CT, Sun SX, **Liu S**, Macahilig C, Katyal M, **Gao X**, Shorr AF. Comparison of disease-severity measures within severe and very severe COPD patients: results from a nationally representative chart review and patient survey. *Int J Chron Obstruct Pulmon Dis*. 2014;9:991-998. doi:10.2147/COPD.S66798.

AbuDagga A, Sun SX, Tan H, **Solem CT**. Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population. *J Med Econ*. 2013;16(3):421-429. doi:10.3111/13696998.2013.766614.

Solem CT, Sun SX, **Sudharshan L**, Macahilig C, Katyal M, **Gao X**. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2013;8:641-652. doi:10.2147/COPD.S51245.

Solem CT, Lee TA, Joo MJ, Lambert BL, Walton SM, Pickard AS. Complexity of medication use in newly diagnosed chronic obstructive pulmonary disease patients. *Am J Geriatr Pharmacother*. 2012;10(2):110-122.e1. doi:10.1016/j.amjopharm.2011.12.003.

Westerhout KY, **Verheggen BG**, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. *J Med Econ*. 2012;15(5):906-917. doi:10.3111/13696998.2012.688904.

Pickard AS, Lee TA, **Solem CT**, Joo MJ, Schumock GT, Krishnan JA. Prioritizing comparative-effectiveness research topics via stakeholder involvement: an application in COPD. *Clin Pharmacol Ther*. 2011;90(6):888-892. doi:10.1038/clpt.2011.237.

Patel DA, **Gao X**, **Stephens JM**, Forshag MS, Tarallo M. US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host. *J Med Econ*. 2011;14(2):227-237. doi:10.3111/13696998.2011.564246.



13 Skin & Subcutaneous Tissue

Botteman MF, Bhanegaonkar AJ, Horodniceanu EG, Ji X, Lee BW, Shek LP, Van Bever HP, Detzel P. Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk, not exclusively breastfed infants in Singapore. *Singapore medical journal*. 2018 Aug;59(8):439.

Klijn SL, van den Reek JMPA, van de **Wetering G**, van der Kolk A, de Jong EMGJ, Kievit W. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. *Br J Dermatol*. 2018 May;178(5):1181-1189. doi: 10.1111/bjd.16247. Epub 2018 Mar 1.

Botteman MF, Bhanegaonkar AJ, **Horodniceanu EG**, Ji X, Lee BW, Shek LP, Van Bever HP, Detzel P. Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk infants not exclusively breastfed in Singapore. *Singapore Med J*. 2018 Aug;59(8):439-448. doi: 10.11622/smedj.2017113. Epub 2017 Dec 7.

Bhanegaonkar A, Horodniceanu EG, Ji X, Detzel P, Boguniewicz M, Chamlin S, Lake A, Czerkies LA, **Botteman MF**, Saavedra JM. Economic burden of atopic dermatitis in high-risk infants receiving cow's milk or partially hydrolyzed 100% whey-based formula. *J Pediatr*. 2015;166(5):1145-1151.e3. doi:10.1016/j.jpeds.2015.02.017.

Bhanegaonkar AJ, Horodniceanu EG, Abdul Latiff AH, Woodhull S, Khoo PC, Detzel P, **Ji X, Botteman MF**. Economic value of atopic dermatitis prevention via infant formula use in high-risk Malaysian infants. *Asia Pac Allergy*. 2015;5(2):84-97. doi:10.5415/apallergy.2015.5.2.84.

Botteman M, Detzel P. Cost-effectiveness of partially hydrolyzed whey protein formula in the primary prevention of atopic dermatitis in high-risk urban infants in Southeast Asia. *Ann Nutr Metab*. 2015;66(suppl 1):26-32. doi:10.1159/000370222.

Saavedra JM, Boguniewicz M, Chamlin S, Lake A, Nedorost S, Czerkies LA, **Patel V, Botteman MF, Horodniceanu EG**. Patterns of clinical management of atopic dermatitis in infants and toddlers: a survey of three physician specialties in the United States. *J Pediatr*. 2013;163(6):1747-1753. doi:10.1016/j.jpeds.2013.06.073.

Jolly M, Pickard AS, Sequeira W, Wallace DJ, **Solem CT**, Mikolaitis RA, Fogg L, Weisman MH, Block JA, Cash TF. A brief assessment tool for body image in systemic lupus erythematosus. *Body Image*. 2012;9(2):279-284. doi:10.1016/j.bodyim.2011.11.001.

Watson JM, Kang'ombe AR, Soares MO, **Chuang LH**, Worthy G, Bland JM, Iglesias C, Cullum N, Torgerson D, Nelson EA; VenUS III Team. VenUS III: a randomised



controlled trial of therapeutic ultrasound in the management of venous leg ulcers. *Health Technol Assess.* 2011;15(13):1-192. doi:10.3310/hta15130.

Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, **Botteman MF**. Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations. *Vaccine.* 2009 Jul 23;27(34):4694-703. doi: 10.1016/j.vaccine.2009.05.062. Epub 2009 Jun 9.



14 Ophthalmology

Chirikov VV, Shah R, Kwon Y, Patel D. Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. *Ophthalmic Epidemiol.* 2018 Sep 10:1-20. doi: 10.1080/09286586.2018.1513042. [Epub ahead of print]

Bennison C, Stephens S, Lescauwaet B, **van Hout B,** Jackson TL. Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole. *J Mark Access Health Policy.* 2016;4(1):31472. doi:10.3402/jmahp.v4.31472.

Miskala PH. Development, use, and interpretation of patient-reported outcomes for clinical decision making in ophthalmology. *JAMA Ophthalmol.* 2016;134(6):690-692. doi:10.1001/jamaophthalmol.2016.0820.

McDonald M, **Patel DA,** Keith MS, **Snedecor SJ.** Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review. *Ocul Surf.* 2016 Apr;14(2):144-67. doi: 10.1016/j.jtos.2015.11.002. Epub 2015 Dec 28.

Bartlett JD, Keith MS, **Sudharshan L, Snedecor SJ.** Associations between signs and symptoms of dry eye disease: a systematic review. *Clin Ophthalmol.* 2015;9:1719-1730. doi:10.2147/OPTH.S89700.



15 Other

Devlin NJ, Shah KK, Mulhern BJ, **Pantiri K, van Hout B**. A new method for valuing health: directly eliciting personal utility functions. *Eur J Health Econ*. 2018 Jul 20. doi: 10.1007/s10198-018-0993-z. [Epub ahead of print]

Quigley JM, Thompson JC, **Halfpenny NJ**, Scott DA. Critical appraisal of nonrandomized studies-A review of recommended and commonly used tools. *J Eval Clin Pract*. 2018 Feb 27. doi: 10.1111/jep.12889. [Epub ahead of print]

Ara R, Peasgood T, Mukuria C, Chevrou-Severac H, Rowen D, Azzabi-Zourag I, Paisley S, Young T, **van Hout B**, Brazier J. Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care. *Pharmacoeconomics*. 2017 Oct 19. doi: 10.1007/s40273-017-0543-z.

Rowen D, Azzabi Zourag I, Chevrou-Severac H, **van Hout B**. International Regulations and Recommendations for Utility Data for Health Technology Assessment. *Pharmacoeconomics*. 2017 Oct 19. doi: 10.1007/s40273-017-0544-y.

Cooke CE, **Stephens JM**. Clinical, economic, and humanistic burden of needlestick injuries in healthcare workers. *Med Devices (Auckl)*. 2017 Sep 29;10:225-235. doi: 10.2147/MDER.S140846.

Devlin NJ, Shah KK, Feng Y, Mulhern B, **van Hout B**. Valuing health-related quality of life: An EQ-5D-5L value set for England. *Health Econ*. 2017 Aug 22. doi: 10.1002/hec.3564.

Feng Y, Devlin NJ, Shah KK, Mulhern B, **van Hout B**. New methods for modelling EQ-5D-5L value sets: An application to English data. *Health Econ*. 2017 Aug 18. doi: 10.1002/hec.3560.

Ijzerman MJ, Koffijberg H, **Fenwick E**, Krahn M. Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature. *Pharmacoeconomics*. 2017.

Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, **Botteman M**, Busschbach J. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. *Value Health*. 2017;20(1):18-27. doi:10.1016/j.jval.2016.11.006.

Charokopou M. Using health economic models to help guide healthcare decisions. *Curr Med Res Opin*. 2016;32(2):205-206. doi:10.1185/03007995.2015.1102721.



Thurston SJ, **Craig D**, Wilson P, Drummond MF. Increasing decision-makers' access to economic evaluations: alternative methods of communicating the information. *Int J Technol Assess Health Care*. 2008 Spring;24(2):151-7. doi: 10.1017/S0266462308080215.

Mercer SW, Fitzpatrick B, Guthrie B, **Fenwick E**, Grieve E, Lawson K, Boyer N, McConnachie A, Lloyd SM, O'Brien R, Watt GCM, Wyke S. The CARE Plus study – a whole-system intervention to improve quality of life of primary care patients with multimorbidity in areas of high socioeconomic deprivation: exploratory cluster randomised trial and cost-utility analysis. *BMC Medicine*. 2016. 14:88.

Rowen D, Brazier J, **van Hout B**. A comparison of methods for converting DCE values onto the full health-dead QALY scale. *Med Decis Making*. 2015;35(3):328-340. doi:10.1177/0272989X14559542.

Stollenwerk B, Lhachimi S, Briggs A, **Fenwick E**, Caro J, Siebert U, Danner M, Gerber-Grote A. Communicating the Parameter Uncertainty in the IQWiG Efficiency Frontier to Decision-Makers. *Health Economics*. 2015, 24 (4): 481-490.

Geue C, Wu O, Xin Y, Heggie R, Hutchinson S, Martin N, **Fenwick E**, Goldberg D. Cost-Effectiveness of HBV and HCV Screening Strategies – A Systematic Review of Existing Modelling Techniques. *PLoS One*. 2015. 10 (12).

Lorgelly P, Lorimer K, **Fenwick E**, Briggs A, Anand P. Operationalising the Capability Approach as an outcome measure in public health: the development of the OCAP-18. *Social Science & Medicine*. 2015. 142: 68-81.

Charokopou M, Majer IM, de Raad J, Broekhuizen S, Postma M, **Heeg B**. Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013. *Value Health*. 2015;18(2):284-291. doi:10.1016/j.jval.2014.12.008.

Krabbe PF, Devlin NJ, Stolk EA, Shah KK, Oppe M, **van Hout B**, Quik EH, Pickard AS, Xie F. Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5L health-state values. *Med Care*. 2014;52(11):935-943. doi:10.1097/MLR.0000000000000178.

Mohiuddin S, **Fenwick E**, Payne K. Use of Value of information in UK health technology assessments. *International Journal of Technology Assessment in Health Care*. 2014, 30 (6): 553-570.



Oppe M, Devlin NJ, **van Hout B**, Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. *Value Health*. 2014;17(4):445-453. doi:10.1016/j.jval.2014.04.002.

Sexton E, **King-Kallimanis BL**, Morgan K, McGee H. Development of the brief ageing perceptions questionnaire (B-APQ): a confirmatory factor analysis approach to item reduction. *BMC Geriatr*. 2014;14:44. doi:10.1186/1471-2318-14-44.

Baeten S, Van Ourti T, van Doorslaer E. Rising inequalities in income and health in China: who is left behind? *J Health Econ*. 2013;32(6):1214-29.

Fenwick E, Macdonald C, Thomson H. Economic analysis of the health impacts of housing improvement studies: a systematic review. 2013, 67 (10): 835-845.

Lawson K, Kearns A, Petticrew M, **Fenwick E**. Investing in health: is social housing value for money? A cost-utility analysis. *Journal of Epidemiology and Community Health*. 2013, 67 (10): 829-834.

Briggs AH, Weinstein MC, **Fenwick E**, Karnon J, Sculpher MJ and Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group - 6. *Medical Decision Making*. 2012, 32 (5): 722-732.

Briggs AH, Weinstein MC, **Fenwick E**, Karnon J, Sculpher MJ and Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group - 6. *Value in Health*. 2012, 15 (6): 835-842.

Boyd K, Briggs A, **Fenwick E**, Norrie J, Stock S. Power and sample size for cost-effectiveness analysis: fFN neonatal screening. *Contemporary Clinical Trials*. 2011, 32 (6): 893-901. ISSN 1551-7144.

Shaw R, **Fenwick E**, Baker G, McAdam C, Fitzsimons C and Mutrie N. 'Pedometers cost buttons': the feasibility of implementing a pedometer based walking programme within the community. *BMC Public Health*. 2011, 11: 200. ISSN 1471-2458.

Patel DA, Holdford DA, Edwards E, Carroll NV. Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States. *J Allergy Clin Immunol*. 2011;128(1):110-115.e5. doi:10.1016/j.jaci.2011.03.013.

Boyd K, **Fenwick E**. and Briggs A. Using an iterative approach to economic evaluation in the drug development process. *Drug Development Research*. 2010, 71 (8): 470-477. ISSN 0272-4391.



Walker S, Mason A, Claxton K, Cookson R, **Fenwick E**, Fleetcroft R, Sculpher M. Value for money and the Quality and Outcomes Framework in Primary Care in the UK NHS. *British Journal of General Practice*. 2010, 60 (574): 213-220. ISSN 0960-1643.

Briggs AH, Ritchie K, **Fenwick E**, Chalkidou K, Littlejohns P. Access with evidence development in the UK: past experiences, current initiatives and future potential. *PharmacoEconomics*. 2010, 28 (2): 163-170.

Lorgelly P, Lawson K, **Fenwick E**, Briggs A. Outcome Measurement in Economic Evaluations of Public Health Interventions: a Role for the Capability Approach? *International Journal of Environmental Research and Public Health*. 2010, 7: 2274-2289. ISSN 1660-4601

Barton G, Briggs A, **Fenwick E**. **Optimal Cost-Effectiveness Decisions: The Role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI)**. *Value in Health*. 2008, 11 (5): 886-897. ISSN 10983015

Fitzsimons C, Baker G, Wright A, Nimmo M, Ward Thompson C, Lowry R, Millington C, Shaw R, **Fenwick E**, Ogilvie D, Inchley J, Foster C, Mutrie N. The 'Walking for Wellbeing in the West' randomised controlled trial of a pedometer-based walking programme in combination with physical activity consultation with 12 month follow-up: rationale and study design. *BMC Public Health*. 2008, 8: 259. ISSN 1471-2458

Fenwick E, Claxton K and Sculpher M. The value of implementation and the value of information: combined and uneven development. *Medical Decision Making*. 2008, 28 (1): 21-32. ISSN 0272-989X

Fenwick E, Palmer S, Claxton K, Sculpher M, Abrams K and Sutton A. An iterative Bayesian approach to health technology assessment: Application to a policy of pre-operative optimisation for patients undergoing major elective surgery. *Medical Decision Making*. 2006, 26 (5):480-96.

Severens JL, Brunenberg DEM, **Fenwick E**, O'Brien B, Joore MA. Cost-effectiveness acceptability curves and a reluctance to lose. *Pharmacoeconomics*. 2005, 23 (12): 1207-1214.

O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, **Fenwick E**, Fryback D, Sculpher M, Spiegelhalter D, Willan A. Incorporation of uncertainty in health economic modelling studies – The authors' reply. *Pharmacoeconomics*. 2005, 23 (8): 853.

O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, **Fenwick E**,



Fryback D, Sculpher M, Spiegelhalter D, Willan A. Incorporation of uncertainty in health economic modelling studies. *Pharmacoeconomics*. 2005, 23 (6): 529-536.

Fenwick E, O'Brien B, Briggs A. Cost-effectiveness acceptability curves – Facts, fallacies and FAQ. *Health Economics*. 2004, 13 (5): 405-415.

Fenwick E, Wilson RJ, Sculpher M, Claxton K. Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: A cost-effectiveness analysis. *Intensive Care Medicine*. 2002, 28 (5): 599-608.

Fenwick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. *Health Economics*. 2001, 10 (8): 779-787.

Sculpher M, **Fenwick E**, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. *Pharmacoeconomics*. 2000, 17 (5): 461-477.

